

Indian firm Intas Pharma inks new licensing agreement for treating autoimmune diseases in 150+ countries

20 December 2023 | News

Intas gains exclusive commercialisation rights for the Etanercept biosimilar, for more than 150 countries worldwide



Intas Pharmaceuticals, a leading multinational pharmaceutical company in India, has announced a strategic exclusive licensing agreement with Spanish company mAbxience (a Fresenius Kabi majority-owned group with partial ownership from Insud Pharma) for a biosimilar for Etanercept.

Etanercept is a dimeric fusion protein with tumor necrosis factor (TNF) blocking action that was approved for use over 20 years ago, offering patients a valuable therapeutic option for treating various autoimmune diseases. According to IQVIA, global sales of Etanercept for 12 months, ending June 2023, were \$ 11B.

This agreement accelerates Intas' global mission to enable innovative and affordable treatment options for autoimmune diseases. In the partnership arrangement, Intas receives exclusive rights to commercialise Etanercept biosimilars, through its affiliates, for the treatment of various autoimmune diseases, in more than 150 countries across the globe, includingEurope and the United States of America, leveraging strong sales, marketing capabilities and experience in successfully commercializing new biosimilars.

mAbxience will be responsible for the development, manufacturing, and supply of the Etanercept biosimilar from its state-of-the-art, Good Manufacturing Practices (GMP) approved facilities.